Skip to main content
PYXS logo

Pyxis Oncology, Inc.

PYXSNASDAQHealthcareBiotechnology

$1.68Today:- (-)1Y −46.43%

As of Oct 16, 2026 close

Market cap
$115.18M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.03$5.55
Volume (live)
-
Avg. volume (3M)
1.32M

Pyxis Oncology (PYXS) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Pyxis Oncology used $63.50M of cash in operating activities and spent $9.00K on capital expenditures. That left free cash flow of −$63.51M. It repurchased $148.00K of its own shares.

Pyxis Oncology Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Pyxis Oncology, Inc. (PYXS) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-79.62-77.33-73.79-120.72-75.98-12.83-2.77
Depreciation & Amortization4.512.981.930.710.650.470.00
Deferred Income Tax0.000.000.000.006.280.000.00
Stock Based Compensation11.8012.9516.9515.766.440.040.03
Change in Working Capital1.94-11.82-11.664.506.681.870.51
Change in Accounts Payable6.031.20-3.51-8.334.640.560.29
Change in Other Working Capital-1.260.700.6612.832.031.310.21
Other Operating Activities-2.140.700.6610.4120.600.37-0.26
Net Cash from Operating Activities-63.50-57.67-70.71-89.34-35.33-10.08-2.24
Investing Activities
Capital Expenditures-0.01-0.24-6.73-6.40-0.54-1.480.00
Acquisitions0.000.006.660.00-0.050.000.00
Purchases of Investments-107.01-160.12-196.830.00-0.050.000.00
Sales/Maturities of Investments165.87168.5192.050.000.050.000.00
Other Investing Activities0.000.000.000.000.000.000.00
Net Cash from Investing Activities58.868.16-104.85-6.40-0.59-1.480.00
Financing Activities
Common Stock Issued0.7459.056.120.00152.300.040.01
Common Stock Repurchased0.150.240.000.000.000.000.00
Other Financing Activities-0.15-0.24-0.450.18151.750.0343.90
Net Cash from Financing Activities0.5959.335.930.18304.040.0421.96
Summary
Net Change in Cash-4.059.81-169.63-95.55268.13-11.5319.72
Cash at Beginning of Period20.9511.14180.77276.328.1919.720.00
Cash at End of Period16.8920.9511.14180.77276.328.1919.72
Free Cash Flow-63.51-57.91-77.44-95.73-35.87-11.57-2.24
Supplemental Disclosures
Interest Paid-0.010.00----
Income Taxes Paid-0.160.050.02---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Pyxis Oncology Cash Flow

What is Pyxis Oncology's free cash flow?

Pyxis Oncology had negative free cash flow of $63.51M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$63.50M minus $9.00K of capital expenditures.

How much does Pyxis Oncology spend on capital expenditures?

Pyxis Oncology spent $9.00K on capital expenditures in fiscal 2025, compared with $237.00K a year earlier.

Does Pyxis Oncology pay dividends or buy back shares?

Yes. In fiscal 2025 Pyxis Oncology returned $148.00K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition